Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth company less than two ...

Hims & Hers’ stock price has swung wildly this year. The telehealth company’s public feud with drugmaker Novo Nordisk knocked off a nearly a third of its valuation on Monday.

Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of illegally selling cheaper copycats of Novo Nordisk’s weight-loss drug ...

Should you buy HIMS stock at $57?Lofty Valuations HIMS stock is deemed expensive by most metrics. The company trades at 6.6 times its sales, which is more than double the S&P 500’s 3.0 ratio ...

Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111 ...

HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to find out why HIMS stock is a Hold.